Washington, DC 20549


Current Report

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2023

CytoDyn Inc.

(Exact name of registrant as specified in its charter)




(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

1111 Main Street, Suite 660

Vancouver, Washington 98660

(Address of principal executive offices, including zip code)

(360) 980-8524

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class


Trading Symbol(s)


Name of each exchange on which registered




Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         

Item 4.01. Changes in Registrant’s Certifying Accountant.

On October 6, 2023, the Audit Committee engaged BF Borgers CPA PC (“BF Borgers”) and appointed the firm as the Company’s independent registered public accounting firm for the Company’s fiscal year ended May 31, 2024. Representatives of BF Borgers are expected to attend the Company’s annual meeting of stockholders to be held on November 9, 2023 (the “Annual Meeting”) and to be available to respond to appropriate questions, and will have an opportunity to make a statement if they desire to do so.

The appointment of BF Borgers followed the resignation of the Company’s former independent registered public accounting firm, Macias Gini & O’Connell LLP (“MGO”), as previously reported in the Company’s Form 8-K filed on September 25, 2023. Representatives of MGO are not expected to attend the Annual Meeting.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: October 10, 2023


/s/ Antonio Migliarese

Antonio Migliarese

Chief Financial Officer and Interim President

Document and Entity Information
Oct. 06, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Oct. 06, 2023
Entity Registrant Name CytoDyn Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 000-49908
Entity Tax Identification Number 83-1887078
Entity Address, Address Line One 1111 Main Street
Entity Address, Adress Line Two Suite 660
Entity Address, City or Town Vancouver
Entity Address State Or Province WA
Entity Address, Postal Zip Code 98660
City Area Code 360
Local Phone Number 980-8524
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001175680
Amendment Flag false

Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more CytoDyn (QB) Charts.
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more CytoDyn (QB) Charts.